Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned

Carola A.S. Arndt, Gianni Bisogno, Ewa Koscielniak

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

We review and summarize the highlights of almost five decades of cooperative group trials in rhabdomyosarcoma on both sides of the Atlantic, concentrating on chemotherapy regimens, what has been learned, and where remaining challenges are. The most important achievements have been to decrease or omit the dose of alkylator therapy for many patients, to clarify after much controversy that doxorubicin does not improve the outcome of patients even in the highest risk groups, and to show that high dose chemotherapy and stem cell rescue do not improve the outcome of the highest risk patients. In North America, vincristine/actinomycin/cyclophosphamide (VAC) remains an important part of therapy, whereas in Europe the alkylating agent of choice is ifosfamide. The highest risk patients, namely those with the poorest prognostic score, have had no improvement in outcome since the first cooperative group trial in 1972 and remain the greatest challenge. Philosophical differences between European and North American strategies still revolve somewhat around the total burden of therapy received, that is should certain groups of patients be spared aggressive local control in order to reduce late effects, recognizing that it is not possible to identify priori the children that can be cured with this approach exposing the whole population to a higher risk of relapse. Collaboration and joining resources may help answer some difficult questions.

Original languageEnglish (US)
Pages (from-to)94-101
Number of pages8
JournalCancer Treatment Reviews
Volume68
DOIs
StatePublished - Jul 1 2018

Fingerprint

Rhabdomyosarcoma
Alkylating Agents
Drug Therapy
Ifosfamide
Dactinomycin
Vincristine
North America
Doxorubicin
Cyclophosphamide
Stem Cells
Therapeutics
Recurrence
Population

Keywords

  • Clinical trials
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. / Arndt, Carola A.S.; Bisogno, Gianni; Koscielniak, Ewa.

In: Cancer Treatment Reviews, Vol. 68, 01.07.2018, p. 94-101.

Research output: Contribution to journalReview article

@article{ad89ad724e4240b7821232115a9a3bce,
title = "Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned",
abstract = "We review and summarize the highlights of almost five decades of cooperative group trials in rhabdomyosarcoma on both sides of the Atlantic, concentrating on chemotherapy regimens, what has been learned, and where remaining challenges are. The most important achievements have been to decrease or omit the dose of alkylator therapy for many patients, to clarify after much controversy that doxorubicin does not improve the outcome of patients even in the highest risk groups, and to show that high dose chemotherapy and stem cell rescue do not improve the outcome of the highest risk patients. In North America, vincristine/actinomycin/cyclophosphamide (VAC) remains an important part of therapy, whereas in Europe the alkylating agent of choice is ifosfamide. The highest risk patients, namely those with the poorest prognostic score, have had no improvement in outcome since the first cooperative group trial in 1972 and remain the greatest challenge. Philosophical differences between European and North American strategies still revolve somewhat around the total burden of therapy received, that is should certain groups of patients be spared aggressive local control in order to reduce late effects, recognizing that it is not possible to identify priori the children that can be cured with this approach exposing the whole population to a higher risk of relapse. Collaboration and joining resources may help answer some difficult questions.",
keywords = "Clinical trials, Rhabdomyosarcoma",
author = "Arndt, {Carola A.S.} and Gianni Bisogno and Ewa Koscielniak",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.ctrv.2018.06.013",
language = "English (US)",
volume = "68",
pages = "94--101",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned

AU - Arndt, Carola A.S.

AU - Bisogno, Gianni

AU - Koscielniak, Ewa

PY - 2018/7/1

Y1 - 2018/7/1

N2 - We review and summarize the highlights of almost five decades of cooperative group trials in rhabdomyosarcoma on both sides of the Atlantic, concentrating on chemotherapy regimens, what has been learned, and where remaining challenges are. The most important achievements have been to decrease or omit the dose of alkylator therapy for many patients, to clarify after much controversy that doxorubicin does not improve the outcome of patients even in the highest risk groups, and to show that high dose chemotherapy and stem cell rescue do not improve the outcome of the highest risk patients. In North America, vincristine/actinomycin/cyclophosphamide (VAC) remains an important part of therapy, whereas in Europe the alkylating agent of choice is ifosfamide. The highest risk patients, namely those with the poorest prognostic score, have had no improvement in outcome since the first cooperative group trial in 1972 and remain the greatest challenge. Philosophical differences between European and North American strategies still revolve somewhat around the total burden of therapy received, that is should certain groups of patients be spared aggressive local control in order to reduce late effects, recognizing that it is not possible to identify priori the children that can be cured with this approach exposing the whole population to a higher risk of relapse. Collaboration and joining resources may help answer some difficult questions.

AB - We review and summarize the highlights of almost five decades of cooperative group trials in rhabdomyosarcoma on both sides of the Atlantic, concentrating on chemotherapy regimens, what has been learned, and where remaining challenges are. The most important achievements have been to decrease or omit the dose of alkylator therapy for many patients, to clarify after much controversy that doxorubicin does not improve the outcome of patients even in the highest risk groups, and to show that high dose chemotherapy and stem cell rescue do not improve the outcome of the highest risk patients. In North America, vincristine/actinomycin/cyclophosphamide (VAC) remains an important part of therapy, whereas in Europe the alkylating agent of choice is ifosfamide. The highest risk patients, namely those with the poorest prognostic score, have had no improvement in outcome since the first cooperative group trial in 1972 and remain the greatest challenge. Philosophical differences between European and North American strategies still revolve somewhat around the total burden of therapy received, that is should certain groups of patients be spared aggressive local control in order to reduce late effects, recognizing that it is not possible to identify priori the children that can be cured with this approach exposing the whole population to a higher risk of relapse. Collaboration and joining resources may help answer some difficult questions.

KW - Clinical trials

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85048875021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048875021&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2018.06.013

DO - 10.1016/j.ctrv.2018.06.013

M3 - Review article

C2 - 29940525

AN - SCOPUS:85048875021

VL - 68

SP - 94

EP - 101

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -